SCHEMBL1784631

SCHEMBL1784631

O=C(O)N1CCC(Nc2nc(Cl)ncc2[N+](=O)[O-])CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 4/20 0.48
GSK3A P49840 2/20 0.42
GSK3B P49841 2/20 0.42
HSD11B1 P28845 1/20 0.42
ABL1 P00519 1/20 0.41
BCR P11274 1/20 0.41
CDK2 P24941 1/20 0.40
KMT2A Q03164 1/20 0.40
TRPV1 Q8NER1 1/20 0.38
MAPK1 P28482 1/20 0.37
PAK1 Q13153 2/20 0.36
POLB P06746 2/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
AXL P30530 1/20 0.36
EGFR P00533 1/20 0.36
BTK Q06187 1/20 0.36
HCAR3 P49019 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19665640 0.93 HSD11B1 (0.47) PIN1GSK3AGSK3BHSD11B1ABL1
SCHEMBL15974992 0.88 PIN1 (0.50) PIN1GSK3AGSK3BHSD11B1ABL1
SCHEMBL17388662 0.88 PIN1 (0.50) PIN1GSK3AGSK3BHSD11B1ABL1
SCHEMBL14841407 0.87 PIN1 (0.45) PIN1GSK3AGSK3BHSD11B1ABL1
SCHEMBL17388653 0.87 PIN1 (0.45) PIN1GSK3AGSK3BHSD11B1ABL1
SCHEMBL1804937 0.85 PIN1 (0.56) PIN1GSK3AGSK3BCDK2KMT2A
SCHEMBL1779986 0.84 ALDH1A1 (0.47) CDK2MAPK1ALDH1A1LMNAMAPT
SCHEMBL19666573 0.83 PIN1 (0.50) PIN1GSK3AGSK3BCDK2KMT2A
SCHEMBL20837955 0.83 PIN1 (0.50) PIN1GSK3AGSK3BCDK2KMT2A
SCHEMBL17649495 0.83 PIN1 (0.50) PIN1GSK3AGSK3BCDK2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3464287-B1 ANIMAL AND HUMAN ANTI-MALARIAL AGENTS CELGENE CORP (US) 2022-06-08 EP disclosed
US-11344554-B2 Animal and human anti-malarial agents CELGENE CORPORATION (US) 2022-05-31 US disclosed
CN-109563095-B Animal and human antimalarial agents 细胞基因公司 2021-10-29 CN disclosed
US-20200330469-A1 ANIMAL AND HUMAN ANTI-MALARIAL AGENTS CELGENE CORP (US) 2020-10-22 US disclosed
US-10736899-B2 Animal and human anti-malarial agents CELGENE CORPORATION (US) 2020-08-11 US disclosed
US-10420771-B2 Animal and human anti-malarial agents CELGENE CORPORATION (US) 2019-09-24 US disclosed
EP-3464287-A1 ANIMAL AND HUMAN ANTI-MALARIAL AGENTS Celgene Corporation (US) 2019-04-10 EP disclosed
US-20180280398-A1 ANIMAL AND HUMAN ANTI-MALARIAL AGENTS CELGENE CORP (US) 2018-10-04 US disclosed
US-10016436-B2 Animal and human anti-malarial agents CELGENE CORPORATION (US) 2018-07-10 US disclosed
WO-2017210399-A1 ANIMAL AND HUMAN ANTI-MALARIAL AGENTS CELGENE CORPORATION (US) 2017-12-07 WO disclosed
US-20170348316-A1 ANIMAL AND HUMAN ANTI-MALARIAL AGENTS CELGENE CORPORATION 2017-12-07 US disclosed
US-9708326-B2 Inhibitors of bruton's tyrosine kinase PHARMACYCLICS LLC (US) 2017-07-18 US disclosed
US-20160002241-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS, LLC. (US) 2016-01-07 US disclosed
WO-2014130693-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS, INC. (US) 2014-08-28 WO disclosed
US-20110118238-A1 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2011-05-19 US disclosed
EP-2212326-A1 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AstraZeneca AB (SE) 2010-08-04 EP disclosed
WO-2009024824-A1 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200330469-A1 ANIMAL AND HUMAN ANTI-MALARIAL AGENTS HPRT1, UMPS, PNP PIN1 3360/4885GSK3A 2053/4885GSK3B 2206/4885
US-20170348316-A1 ANIMAL AND HUMAN ANTI-MALARIAL AGENTS HPRT1, NUDT1, UMPS PIN1 2639/4885GSK3A 1636/4885GSK3B 1744/4885
US-20110118238-A1 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS BUB1, BUB1B, TTBK1 PIN1 1298/4885GSK3A 953/4885GSK3B 980/4885
US-10420771-B2 Animal and human anti-malarial agents HPRT1, UMPS, PNP PIN1 3378/4885GSK3A 2117/4885GSK3B 2275/4885
US-10736899-B2 Animal and human anti-malarial agents HPRT1, UMPS, PNP PIN1 3360/4885GSK3A 2053/4885GSK3B 2206/4885
US-10016436-B2 Animal and human anti-malarial agents HPRT1, NUDT1, UMPS PIN1 2639/4885GSK3A 1636/4885GSK3B 1744/4885
US-11344554-B2 Animal and human anti-malarial agents HPRT1, UMPS, PNP PIN1 3360/4885GSK3A 2053/4885GSK3B 2206/4885
US-20160002241-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, LYN, LCK PIN1 2265/4885GSK3A 160/4885GSK3B 120/4885
US-20180280398-A1 ANIMAL AND HUMAN ANTI-MALARIAL AGENTS HPRT1, UMPS, PNP PIN1 3360/4885GSK3A 2053/4885GSK3B 2206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.